Blog
RSS FeedPosted by Michael Wonder on 12 Jun 2017
Olaratumab recommended for NHS use in England
12 June 2017 - Lartruvo (olaratumab), in combination with doxorubicin, has been recommended by the medicines cost-effectiveness watchdog for England ...
Posted by Michael Wonder on 12 Jun 2017
NICE refuses to expand use of Roche’s IPF drug Esbriet
12 June 2017 - The NICE it remaining steadfast in its position that Roche’s Esbriet should only be funded by ...
Posted by Michael Wonder on 10 Jun 2017
NICE rejects Zurampic for hyperuricaemia in gout patients
9 June 2017 - Cost regulators for the NHS in England and Wales have published draft guidelines barring adults with ...
Posted by Michael Wonder on 07 Jun 2017
New UK law to control generic drug prices – implications for pharma
7 June 2017 - New UK regulation seeks to clarify and extend the Government’s powers to regulate the cost of medicines ...
Posted by Michael Wonder on 06 Jun 2017
NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis
6 June 2017 - Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex ...
Posted by Michael Wonder on 02 Jun 2017
NICE backs Opdivo for classical Hodgkin lymphoma
2 June 2017 - Patients with classical Hodgkin lymphoma living in England and Wales could now become the first to ...
Posted by Michael Wonder on 01 Jun 2017
Britain backs first-line use of Merck's Keytruda under cancer fund
31 May 2017 - Britain's cost-effectiveness agency NICE has decided that Merck & Co's immunotherapy drug Keytruda can be used ...
Posted by Michael Wonder on 01 Jun 2017
NICE backs new drug for Gaucher disease
31 May 2017 - The NICE has issued a positive final appraisal determination recommending Cerdelga (eliglustat) as a first-line treatment ...
Posted by Michael Wonder on 30 May 2017
NICE to launch new evidence tool for medtech product developers
30 May 2017 - NICE is launching an online tool to help medtech companies get their products to patients faster. ...
Posted by Michael Wonder on 29 May 2017
UK’s NICE recommends Novartis’ Afinitor to treat neuroendocrine tumours
29 May 2017 - The UK’s NICE has recommended Novartis’ Afinitor (everolimus) to treat unresectable or metastatic neuroendocrine tumours in patients ...
Posted by Michael Wonder on 24 May 2017
NICE terminates appraisal of afatinib dimaleate
24 May 2017 - NICE was to assess afatinib dimaleate for treatment of patients with advanced squamous non-small-cell lung cancer ...
Posted by Michael Wonder on 24 May 2017
NICE nod for psoriatic arthritis drugs Cimzia and Cosentyx
24 May 2017 - Cost regulators for the NHS in England and Wales are recommending UCB's Cimzia and Novartis' Cosentyx ...
Posted by Michael Wonder on 23 May 2017
US pharma giant Merck & Co. accused of blocking cheaper arthritis drugs for the NHS
23 May 2017 - The US pharmaceuticals giant Merck & Co is accused of abusing its dominance of the market ...
Posted by Michael Wonder on 22 May 2017
NICE updates type 2 guidelines to reflect new advice on drug treatments
18 May 2017 - The NICE has updated its guidelines about drug treatments for people with type 2 diabetes. ...
Posted by Michael Wonder on 18 May 2017
A new health technology assessment system for devices: the first five years
15 May 2017 - The aim of this study was to review 5 years of activity from a new system devised ...